This provides a sustained therapeutic effect on DME and NIU-PS. 61623;Expand our ophthalmic product offerings. In this population, only 15.3% of adults know they had prediabetes. Intravitreal corticosteroid therapies are also used to treat DME. We believe that ILUVIEN continues to be underutilized in the treatment of DME. In our promotional efforts, we focus on three main areas to generate demand for ILUVIEN. The Flextronics Agreement terminated in accordance with the notice on September 30, 2020. We sometimes refer to physician offices, pharmacies, hospitals and clinics as end users. During 2020, we recognized approximately $2.1 million of royalty expense. We licensed our one utility patent right relating to ILUVIEN from EyePoint. The U.K.'s leaving the EU, or "Brexit," could have a material adverse effect on us. We have determined that a Section 382 change in ownership occurred in December of 2015. This requirement is referred to as process validation. We may not receive necessary approvals to commercialize ILUVIEN in any additional market. We may need to amend these claims. The insurance provides worldwide coverage where allowed by law. These fluctuations may be even more pronounced in the trading market for our stock. We also may elect to sell shares of our common stock through an at-the-market offering.
